BET bromodomain proteins are required for glioblastoma cell proliferation-Reference-Cited by-同舟云学术

BET bromodomain proteins are required for glioblastoma cell proliferation

Published:2014-02-19 Issue:4 Volume:9 Page:611-620
ISSN:1559-2294
Container-title:Epigenetics
language:en
Short-container-title:Epigenetics

Author:

Pastori Chiara,Daniel Mark,Penas Clara,Volmar Claude-Henry,Johnstone Andrea L,Brothers Shaun P,Graham Regina M,Allen Bryce,Sarkaria Jann N,Komotar Ricardo J,Wahlestedt Claes,Ayad Nagi G

Publisher

Informa UK Limited

Subject

Cancer Research,Molecular Biology

Link

http://www.tandfonline.com/doi/pdf/10.4161/epi.27906

Reference30 articles.

1. Cancer Epigenetics: From Mechanism to Therapy

2. Targeting Epigenetic Readers in Cancer

3. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

4. Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4

5. Multisite protein modification and intramolecular signaling

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bromodomain inhibitor treatment leads to overexpression of multiple kinases in cancer cells;Neoplasia;2024-11

2. Updates for newly diagnosed and recurrent glioblastoma: a review of recent clinical trials;Current Opinion in Neurology;2024-09-13

3. BRD4 expression and its regulatory interaction with miR-26a-3p, DLG5-AS1, and JMJD1C-AS1 lncRNAs in gastric cancer progression;Discover Oncology;2024-08-16

4. RAPID resistance to BET inhibitors is mediated by FGFR1 in glioblastoma;Scientific Reports;2024-04-23

5. MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma;BMC Cancer;2024-02-16